Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
2 No-Brainer Biotech Stocks to Buy Right Now
01:53pm, Monday, 26'th Sep 2022 The Motley Fool
If one can bear the risk with these stocks, the rewards can be extraordinary.
3 Monster Stocks in the Making
10:14am, Saturday, 24'th Sep 2022 The Motley Fool
These companies are small now. But they have massive long-term growth prospects.
3 Monster Stocks in the Making
06:14am, Saturday, 24'th Sep 2022
These companies are small now. But they have massive long-term growth prospects.
3 Biotech Stocks to Buy Now for Extraordinary Gains
09:16pm, Tuesday, 20'th Sep 2022
Biotech stocks have performed relatively well compared to the broader market of late. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 21% over the past three months compared with a 6% gain for the S&P
The 7 Best Biotech Stocks to Buy
01:45pm, Tuesday, 20'th Sep 2022
I've written before about how biotech is the biggest technology trend of our kids' generation. Naturally, that means many people are looking for the best biotech stocks to buy.
2 Growth Stocks That Could Double in the Next Year
02:10pm, Monday, 19'th Sep 2022 The Motley Fool
Just don't be too quick to press the buy button.
Exelixis: Efforts Continue To Diversify The Pipeline
09:11am, Thursday, 15'th Sep 2022
Performance has been poor over the past five years even as executive compensation remains on the high end. Cabozantinib continues to show promising sales growth and retention of market share in key in
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
01:32pm, Thursday, 08'th Sep 2022
Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.
Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?
12:47pm, Thursday, 08'th Sep 2022
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying On the Dip
05:21am, Saturday, 20'th Aug 2022
These stand-out growth stocks are ripe for the picking following a peak decline of 34% in the Nasdaq Composite.
2 No-Brainer Bio-Tech Stocks to Buy Right Now
10:23am, Saturday, 13'th Aug 2022
These two drug makers have outshined the market this year.
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
02:18pm, Wednesday, 10'th Aug 2022
Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.
Exelixis (EXEL) Beats Q2 Earnings and Revenue Estimates
07:33pm, Tuesday, 09'th Aug 2022
Exelixis (EXEL) delivered earnings and revenue surprises of 10% and 7.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis Handily Beats Second-Quarter Expectations, Retains 2022 Outlook
04:14pm, Tuesday, 09'th Aug 2022
Exelixis easily beat second-quarter expectations and retained its full-year outlook on Tuesday. But EXEL stock was unmoved.
2 Top Biotech Stocks Defying the Bear Market
10:23am, Saturday, 06'th Aug 2022
These drugmakers are flying high right now.
